Olympus Corporation (OCPNF) Stock Price & Analysis
Olympus Corporation (OCPNF) — price $11.53 (0.00%), as of the Nov 19, 2026 trading session; market cap $12.3B. Expected results Feb 12, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Olympus Corporation · OCPNF · Healthcare · Medical - Devices
Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $11.53 | |
| Change on the day | 0.00% | |
| 52-week range | $8.00–$14.00 | |
| Market capitalisation | $12.3B | — |
| Price / earnings (trailing) | 21.38 | |
| Shares traded on the day | 2.0K | |
| Beta (volatility vs the S&P 500) | 0.2 | |
| Dividends per share (last 12 months) | $0.38 | |
| Dividend yield (last 12 months) | 3.29% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Events are in date order; the spacing is not a duration scale. Estimated dates can change.
Other perspectives
Council score for Olympus (OCPNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Olympus (OCPNF), and what does it report?
Short answer
Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. Healthcare / Medical Devices Headquarters: 2951, Ishikawa-machi, Hachioji, TY, 192-8507, JP. It employs 28,138 people and is led by Robert White. In Q1 FY2027 it reported revenue of ¥238.66B and net income of ¥18.96B. The market values it at $12.3B.
What do the latest results show for Olympus (OCPNF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of ¥238.66B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.71B Nov 10, 2026
- Latest report · revenue estimate
- $1.70B Nov 10, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 10, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 10, 2026 | $1.71B | $1.70B | $0.1971 | $0.1407 |
| Aug 7, 2026 | $1.48B | $1.39B | $0.1092 | $0.0531 |
| May 12, 2026 | $1.86B | $1.78B | $0.1414 | $0.0482 |
| Feb 13, 2026 | $1.67B | $1.66B | $0.0821 | $0.1471 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | ¥238.66B | ¥18.96B | ¥17.76 (diluted) |
| Q4 FY2026 | ¥297.14B | ¥24.97B | ¥22.37 (diluted) |
| Q3 FY2026 | ¥261.27B | ¥14.18B | ¥12.85 (diluted) |
| Q2 FY2026 | ¥247.84B | ¥20.20B | ¥18.05 (diluted) |
What are the financial strengths and risks for Olympus (OCPNF)?
Short answer · as of
The distress and quality screens read Altman Z 3.31 · Piotroski F 7. Trailing ratios: ROE 11.8% · ROA 6.0% · current ratio 1.67 · earnings yield 4.8% · free-cash-flow yield 4.6%.
What should you watch next at Olympus (OCPNF)?
Short answer · as of
The next earnings report is expected on Feb 12, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is Olympus scored?
Research dated 2026-09-13.
Olympus differs from a disposable-focused device supplier because its model joins complex endoscopy platforms with procedure tools, reprocessors, repair, maintenance, and system integration. A system placement can support later clinical use and service activity, so the commercial relationship can persist beyond the original equipment shipment.
It also differs from a narrowly clinical manufacturer through microscopes and industrial inspection technologies. Investors comparing Olympus with medical-device peers are therefore comparing a mixed installed-base and precision-instrument model, not merely a stream of surgical product sales.
| Company | Price | Market value | Score |
|---|---|---|---|
| $43.93 Nov 19, 2026 | $15.2B | — Model unavailable | |
| $9.81 Nov 18, 2026 | $16.7B | — Model unavailable | |
| $26.99 Nov 19, 2026 | $15.9B | — Model unavailable | |
| $93.89 Nov 19, 2026 | $16.1B | — Model unavailable | |
| $1.12 Nov 19, 2026 | $12.8B | — Model unavailable | |
| $29.83 Nov 19, 2026 | $12.5B | — 5-pillar · not comparable | |
| $320.00 Nov 19, 2026 | $12.6B | — 5-pillar · not comparable | |
| $163.96 Nov 18, 2026 | $11.6B | — 5-pillar · not comparable | |
| $233.08 Nov 18, 2026 | $13.8B | — 5-pillar · not comparable | |
| $370.17 Nov 18, 2026 | $9.95B | — 5-pillar · not comparable | |
| $139.98 Nov 18, 2026 | $9.71B | — 5-pillar · not comparable | |
| $62.10 Nov 19, 2026 | $9.48B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held OCPNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported OCPNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Olympus (OCPNF)?
- Olympus Announces CMS Valuation and Reimbursement Rates for New ESD CPT Codes
- Olympus (TSE:7733) Stock Looks Reasonable As Shares Sit 28% Lower
- Rafferty Domnick Cunningham & Yaffa On What the FDA’s Latest Warning to Olympus Means for Medical Device Accountability
- Olympus Announces U.S. Launch of New Peripheral EBUS Bronchoscope
OCPNF Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Olympus endoscope repair services matter to the business model?
Repair and maintenance keep endoscopy systems in use and extend Olympus's relationship with the installed base beyond the equipment sale. That service connection can accompany demand for procedure tools, reprocessors, and system integration.
Does Olympus rely solely on hospital endoscopy systems?
Hospital endoscopy is only part of the product set. Olympus also sells therapeutic devices, microscopes, industrial videoscopes, testing equipment, analyzers, biomedical materials, orthopedic equipment, and related services.
What is the OCPNF stock price today?
The last price recorded for Olympus Corporation (OCPNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does OCPNF pay a dividend?
Yes. The dividend yield of Olympus Corporation (OCPNF) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 32 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com